Involvement of advanced glycation end-products, pentosidine and Nε-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats

Toxicology

Volumn 268, Issue 1-2, 2010, Pages 89-97

  Moriyama, Tomoyuki ^a   Kemi, Masayuki ^b   Okumura, Chie ^b   Yoshihara, Kazuhiro ^c   Horie, Toshiharu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Advanced glycation end product; Cardiomyopathy; Doxorubicin; N (Carboxymethyl)lysine; Pentosidine

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; DOXORUBICIN; GLUCOSE; GLUTATHIONE; PENTOSIDINE; PYRIDOXAMINE; SODIUM CHLORIDE; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HISTOPATHOLOGY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ARGININE; BLOOD GLUCOSE; CARDIOMYOPATHIES; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOHISTOCHEMISTRY; LYSINE; MALE; RATS;

RATTUS;

EID: 73749085140     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.12.004     Document Type: Article

References (49)

1. Aebi H. Catalase in vitro. Methods Enzymol. 105 (1984) 121-126
2. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
3. Bidasee K.R., Nallani K., Yu Y., Cocklin R.R., Zhang Y., Wang M., Dincer U.D., and Besch Jr. H.R. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 52 (2003) 1825-1836
4. 2+-ATPase. Diabetes 53 (2004) 463-473
5. Boucek Jr. R.J., Buck S.H., Scott F., Oquist N.L., Fleischer S., and Olson R.D. Anthracycline-induced tension in permeabilized cardiac fibers: evidence for the activation of the calcium release channel of sarcoplasmic reticulum. J. Mol. Cell Cardiol. 25 (1993) 249-259
6. Brownlee M., Cerami A., and Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318 (1988) 1315-1321
7. Buege J.A., and Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 52 (1978) 302-310
8. Chellan P., and Nagaraj R.H. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch. Biochem. Biophys 368 (1999) 98-104
9. Curran C.F., Narang P.K., and Reynolds R.D. Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat. Rev. 18 (1991) 241-252
10. D'Alessandro N., Candiloro V., Crescimanno M., Flandina C., Dusonchet L., Crosta L., and Rausa L. Effects of multiple doxorubicin doses on mouse cardiac and hepatic catalase. Pharmacol. Res. Commun. 16 (1984) 145-151
11. Di Marco A., Gaetani M., and Scarpinato B. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother. Rep. 53 (1969) 33-37
12. Dodd D.A., Atkinson J.B., Olson R.D., Buck S., Cusack B.J., Fleischer S., and Boucek Jr. R.J. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J. Clin. Invest. 91 (1993) 1697-1705
13. Doroshow J.H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43 (1983) 460-472
14. Dyer D.G., Blackledge J.A., Katz B.M., Hull C.J., Adkisson H.D., Thorpe S.R., Lyons T.J., and Baynes J.W. The Maillard reaction in vivo. Z. Ernahrungswiss. 30 (1991) 29-45
15. Friedlander M.A., Wu Y.C., Elgawish A., and Monnier V.M. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. J. Clin. Invest. 97 (1996) 728-735
16. Giardino I., Fard A.K., Hatchell D.L., and Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 47 (1998) 1114-1120
17. Goeptar A.R., Te Koppele J.M., Lamme E.K., Pique J.M., and Vermeulen N.P. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol. Pharmacol. 44 (1993) 1267-1277
18. Griffith O.W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106 (1980) 207-212
19. Gustafson D.L., Swanson J.D., and Pritsos C.A. Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapy. Free Radic. Res. Commun. 19 (1993) 111-120
20. Hartog J.W., Voors A.A., Bakker S.J., Smit A.J., and van Veldhuisen D.J. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart Fail. 9 (2007) 1146-1155
21. Hermansen K., and Wassermann K. The effect of vitamin E and selenium on doxorubicin (Adriamycin) induced delayed toxicity in mice. Acta Pharmacol. Toxicol. (Copenh.) 58 (1986) 31-37
22. Ibrahim M.A., Ashour O.M., Ibrahim Y.F., EL-Bitar H.I., Gomaa W., and Adbel-Rahim S.R. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharm. Res. 60 (2009) 373-381
23. Koti B.C., Vishwanathswamy A.H., Wagawade J., and Thippeswamy. Cardioprotective effect of lipistat against doxorubicin induced myocardial toxicity in albino rats. Pharm. Res. 47 (2009) 41-46
24. Linton S., Davies M.J., and Dean R.T. Protein oxidation and ageing. Exp. Gerontol. 36 (2001) 1503-1518
25. Maillard L. Action des acides amines sur les sucres; formation des melanoidines par voie methodique. CR Acad. Sci. 154 (1912) 66
26. Matsumoto K., Ikeda K., Horiuchi S., Zhao H., and Abraham E.C. Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses. Biochem. Biophys. Res. Commun. 241 (1997) 352-354
27. Mimnaugh E.G., Siddik Z.H., Drew R., Sikic B.I., and Gram T.E. The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. Toxicol. Appl. Pharmacol. 49 (1979) 119-126
28. McCord J.M., and Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244 (1969) 6049-6055
29. Metz T.O., Alderson N.L., Thorpe S.R., and Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys. 419 (2003) 41-49
30. Misko T.P., Moore W.M., Kasten T.P., Nickols G.A., Corbett J.A., Tilton R.G., McDaniel M.L., Williamson J.R., and Currie M.G. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J. Pharmacol. 233 (1993) 119-125
31. Muellenbach E.A., Diehl C.J., Teachey M.K., Lindborg K.A., Archuleta T.L., Harrell N.B., Anderson G., Somoza V., Hasselwander O., Matuschek M., and Henriksen E.J. Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat. Metab. Clin. Exp. 57 (2008) 1465-1472
32. Oliveira P.J., Bjork J.A., Santos M.S., Leino R.L., Froberg M.K., Moreno A.J., and Wallace K.B. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol. 200 (2004) 159-168
33. Olson R.D., McDonald J.S., vanBoxtel C.J., Boerth R.C., Harbison R.D., Slonim A.E., Freeman R.W., and Oates J.A. Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. J. Pharmacol. Exp. Ther. 215 (1980) 450-454
34. Ondrias K., Borgatta L., Kim D.H., and Ehrlich B.E. Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circ. Res. 67 (1990) 1167-1174
35. Onorato J.M., Jenkins A.J., Thorpe S.R., and Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J. Biol. Chem. 275 (2000) 21177-21184
36. Peyroux J., and Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol. Biol. 54 (2006) 405-419
37. Pickering R.G., and Pickering C.E. The effects of reduced dietary intake upon the body and organ weights, and some clinical chemistry and haematological variates of the young Wistar rat. Toxicol. Lett. 21 (1984) 271-277
38. Rabbani N., and Thornalley P.J. Dicarbonyls linked to damage in the powerhorse: glycation of mitochondrial proteins and oxidative stress. Biochem. Soc. Trans. 36 (2008) 1045-1050
39. Rajagopalan S., Politi P.M., Sinha B.K., and Myers C.E. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 48 (1988) 4766-4769
40. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339 (1998) 900-905
41. Singh G., Singh A.T., Abraham A., Bhat B., Mukherjee A., Verma R., Agarwal S.K., Jha S., Mukherjee R., and Burman A.C. Protective effects of Terminalia arjuna against doxorubicin-induced cardiotoxicity. J. Ethnopharmacol. 117 (2008) 123-129
42. Solem L.E., Henry T.R., and Wallace K.B. Disruption of mitochondrial calcium homeostasis in vivo following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 129 (1994) 214-222
43. Soulis T., Cooper M.E., Sastra S., Thallas V., Panagiotopoulos S., Bjerrum O.J., and Jerums G. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 40 (1997) 1141-1151
44. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419 (2003) 31-40
45. Voziyan P.A., and Hudson B.G. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell. Mol. Life Sci. 62 (2005) 1671-1681
46. Yin X., Wu H., Chen Y., and Kang Y.J. Induction of antioxidants by adriamycin in mouse heart. Biochem. Pharmacol. 56 (1998) 87-93
47. Yoshihara K., Nagayama Y., Horiguchi H., Yoshida S., Tohyoh S., Takahashi S., Maruyama H., Saito N., and Beppu M. Acceleration of pentosidine formation by medication. Int. Congr. Ser. 1245 (2002) 425-426
48. You J.S., Pan T.L., and Lee Y.S. Protective effects of Danshen (Salvia Miltiorrhiza) on adriamycin-induced cardiac and hepatic toxicity in rats. Phytother. Res. 21 (2007) 1146-1152
49. Zhou S., Starkov A., Froberg M.K., Leino R.L., and Wallace K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61 (2001) 771-777